Wegovy Users Face Five Times Greater Risk of Sudden Sight Loss Than Ozempic Users

A new study reveals a stark dose-dependent divide in the risk of sudden, permanent vision loss between two of the world's most popular medications — both containing the exact same active ingredient.

The Study That Shocked Ophthalmologists

A sweeping analysis of more than 30.6 million adverse event reports submitted to the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) has found that Wegovy — the high-dose semaglutide injection approved for weight loss — carries nearly five times the risk of ischemic optic neuropathy (ION) compared to Ozempic, its lower-dose counterpart approved for type 2 diabetes [1].

The study, published in the British Journal of Ophthalmology in March 2026, analyzed reports filed between December 2017 and December 2024. Of the 31,774 semaglutide-related adverse event reports identified, 3,070 were attributed to Wegovy and 20,608 to Ozempic [1]. The disparity in total reports reflects Ozempic's earlier market entry in 2017; Wegovy was not approved until 2021.

But the proportional signal was unmistakable. Wegovy was most strongly associated with ION, with 28 reported cases and odds nearly 75 times higher than background rates. Ozempic followed with 47 reported cases and odds approximately 19 times higher. Generic semaglutide formulations showed 85 reports with odds roughly 21 times elevated [1]. Notably, Rybelsus — the oral tablet form of semaglutide used for diabetes — generated no ION signal at all.

The researchers concluded: "This study provides the first evidence of a formulation- and dose-dependent ION risk, with the strongest association observed for Wegovy" [1].

What Is Ischemic Optic Neuropathy?

ION — sometimes described in the medical literature as an "eye stroke" — occurs when blood flow to the optic nerve is interrupted or insufficient, damaging the delicate nerve fibers that carry visual information from the eye to the brain [2]. The most common form, non-arteritic anterior ischemic optic neuropathy (NAION), typically strikes without warning: patients experience sudden, painless vision loss in one eye, often upon waking.

The condition is devastating. There is no effective treatment, and the resulting vision loss is generally permanent [3]. NAION is the most common cause of optic nerve swelling in adults over 50 and the second most common optic neuropathy after glaucoma, affecting an estimated 2.3 to 10.3 people per 100,000 in the United States each year, or roughly 6,000 new cases annually [4].

What makes the semaglutide connection alarming is the scale. With approximately 10 million Americans now taking GLP-1 receptor agonists and that number projected to reach 25 million by 2030, even a very rare side effect translates to thousands of potential cases [5].

The Dose Question: Why Wegovy and Not Ozempic?

Wegovy and Ozempic contain the identical active molecule — semaglutide. The critical difference is dosage: Ozempic is prescribed at up to 2.0 mg weekly for blood sugar control, while Wegovy is dosed at up to 2.4 mg weekly, a 20% higher maximum, for chronic weight management [6].

That seemingly modest increase in dosage appears to carry outsized consequences for the optic nerve. The British Journal of Ophthalmology study's authors hypothesize that "high-dose Wegovy probably drives the stronger association by predisposing to optic nerve hypoperfusion through intravascular volume contraction, hypotension with nocturnal dips" [1]. In simpler terms, the higher dose may more aggressively lower blood pressure and reduce fluid volume, particularly during sleep, starving the optic nerve of the blood flow it needs to survive.

This dose-dependent pattern aligns with a broader principle in pharmacology: the same compound can have dramatically different safety profiles at different concentrations. Wegovy's higher dose produces greater weight loss — adults lose around 15% of body weight over 68 weeks compared to roughly 6.4 kg over 40 weeks with Ozempic — but this enhanced efficacy may come with enhanced vascular risk to the eye [6].

The gender disparity is equally striking. The study found the risk of ION was three times greater in men than women, with male Wegovy users showing odds elevated to 116 times above baseline [1]. Researchers have not yet established why men appear more vulnerable, though anatomical differences in optic nerve structure and different cardiovascular risk profiles are potential factors.

Source: British Journal of Ophthalmology / FDA FAERS

Data as of Mar 11, 2026CSV

A Mounting Body of Evidence

The British Journal of Ophthalmology findings do not exist in isolation. They represent the latest in a cascade of studies that began raising red flags in mid-2024.

The Mass Eye and Ear Study (July 2024): Dr. Joseph Rizzo and colleagues at Mass General Brigham's Mass Eye and Ear — Harvard Medical School's ophthalmology program — analyzed 17,000 patient records and found that diabetic patients on semaglutide were more than four times as likely to develop NAION. For patients using semaglutide for weight loss (without diabetes), the risk was more than seven times higher [7].

"I would not take my findings and use them to recommend that patients stop taking their medications," Dr. Rizzo told Mass General Brigham's newsroom. But he emphasized the findings "merit extra caution" in doctor-patient discussions [7].

The Systematic Review (2025): A comprehensive meta-analysis published in peer-reviewed literature found a pooled hazard ratio of 2.62 for NAION among semaglutide users compared to controls [8]. Crucially, this study identified a time-dependent element: risk elevation became statistically significant only after two years of continuous exposure.

The 180-Country Global Study: An observational study spanning 180 countries, published in the American Journal of Ophthalmology, found semaglutide was linked to significant increases in retinal and vitreous detachment, retinal hemorrhage, and macular edema in addition to optic neuropathy — suggesting the ocular risks may extend well beyond NAION alone [9].

The Large-Scale Database Analysis (2025): A study encompassing 3.34 million patients with diabetes found a nuanced pattern: no elevated NAION risk at one-month to one-year time points, but statistically significant increases at the two- and three-year marks [8]. This delay may explain why the risk was initially missed in shorter clinical trials.

The Regulatory Response — Or Lack Thereof

The regulatory landscape presents a fragmented picture. The European Medicines Agency (EMA), acting on a recommendation from its Pharmacovigilance Risk Assessment Committee, has updated semaglutide product information to include NAION as a "very rare" side effect, potentially affecting up to 1 in 10,000 users [3]. The World Health Organization endorsed this classification in June 2025, recommending revisions to semaglutide's Risk Management Plan [3].

In the United States, however, the situation is markedly different. As of early 2026, Novo Nordisk's drug labels for Ozempic, Wegovy, and Rybelsus still contain no NAION warning [10]. The FDA's Sentinel System is reportedly investigating the link, but no formal regulatory action has been taken.

This transatlantic gap has not gone unnoticed by the legal system. In December 2025, the U.S. Judicial Panel on Multidistrict Litigation created MDL No. 3163 in the Eastern District of Pennsylvania to centralize federal lawsuits alleging that GLP-1 drugs cause NAION-related vision loss [10]. The litigation centers on Novo Nordisk's alleged failure to warn doctors and patients about the increased risk.

The American Academy of Ophthalmology (AAO) and the North American Neuro-Ophthalmology Society (NANOS) have issued joint guidance advising that patients experiencing sudden vision loss while on semaglutide should seek immediate medical attention and discuss potential discontinuation with their physicians [11].

The Mechanisms: What Science Suspects

The biological pathway from semaglutide injection to optic nerve damage remains under active investigation. Several hypotheses have emerged:

Rapid glucose reduction. GLP-1 drugs are extraordinarily effective at lowering blood sugar. Researchers hypothesize that rapid blood glucose drops can cause swelling in the optic nerve, particularly in patients whose vascular supply to the nerve is already compromised [7][12].

Hypotension and volume contraction. Semaglutide, especially at Wegovy's higher dose, can cause significant weight loss accompanied by drops in blood pressure and reduced intravascular fluid volume. The optic nerve head is particularly sensitive to perfusion pressure, and overnight dips in blood pressure may push blood flow below critical thresholds [1].

Sympathetic nervous system activation. Some researchers theorize that GLP-1 drugs may activate the sympathetic nervous system, narrowing blood vessels and further limiting blood flow to the optic nerve [12].

Anatomical vulnerability. NAION is most common in patients with a "disc at risk" — a small, crowded optic nerve head where nerve fibers are tightly packed. This structural feature, present in a significant portion of the population, may predispose certain individuals to ischemic injury when combined with pharmacological stressors [4].

10 Million Users and Counting

The findings arrive at a moment when GLP-1 drugs have become one of the most commercially significant pharmaceutical categories in modern history. The global GLP-1 receptor agonist market was valued at $70.08 billion in 2025 and is projected to reach $86.93 billion in 2026 [5]. Novo Nordisk's semaglutide products — Ozempic, Wegovy, and Rybelsus — hold approximately 49% of that market.

In the United States alone, GLP-1 drugs generated $52.7 billion in revenue in 2025. Roughly one in eight American adults has used a GLP-1 drug, according to an American Medical Association survey [5]. In February 2026, Novo Nordisk announced broad U.S. availability of the Wegovy pill, introducing the first oral GLP-1 receptor agonist approved for adult weight loss — a development that could further expand the user base [5].

Source: GDELT Project

Data as of Mar 11, 2026CSV

The sheer volume of patients creates a statistical reality that regulators cannot ignore. Even at the EMA's estimated NAION rate of 1 in 10,000 users per year, 10 million American GLP-1 users would mean approximately 1,000 cases annually — a substantial increase over the baseline of roughly 6,000 U.S. NAION cases per year from all causes [3][4]. If the British Journal of Ophthalmology data is correct that Wegovy's risk is nearly five times that of Ozempic, the burden would fall disproportionately on weight-loss patients.

What Patients Should Know

Ophthalmologists stress that the absolute risk remains low. NAION, even with the elevated odds associated with semaglutide, is a rare condition. The benefits of GLP-1 drugs for diabetes management and cardiovascular risk reduction are well-established and significant.

But "rare" is not "zero," and the consequences of NAION are irreversible. The WHO advises that patients experiencing "sudden loss of vision or rapidly worsening eyesight during treatment" should contact their physician immediately [3]. Treatment discontinuation is recommended upon confirmed NAION diagnosis.

Dr. Rizzo's counsel remains measured: patients with existing vision problems should engage in "mutually engaged" discussions with their doctors, weighing the cardiovascular and metabolic benefits of semaglutide against the potential — if uncommon — ocular risks [7].

For the millions of Americans taking Wegovy specifically for weight management, the calculus may be different than for diabetic patients on Ozempic. Weight loss, while beneficial, is generally a less immediately life-threatening indication than uncontrolled diabetes. Whether the additional 0.4 mg of semaglutide that separates Wegovy from Ozempic justifies the apparent additional eye risk is a question that prescribers and patients now must confront — ideally before the five-times risk differential on the FAERS data makes the decision for them.

The Road Ahead

The British Journal of Ophthalmology study's authors are calling for "urgent prospective evaluation" — randomized, controlled studies specifically designed to measure ION incidence across different semaglutide doses and formulations [1]. Such studies would take years to complete, and the pharmaceutical economics are not in their favor: Novo Nordisk has little commercial incentive to fund research that might restrict the use of its most profitable product line.

In the meantime, the evidence continues to accumulate. A systematic review published in early 2025 found a pooled hazard ratio of 2.62 for NAION across all semaglutide formulations [8]. The new British Journal data suggests that pooled figure masks a significant spread — with Wegovy at the high end and Rybelsus apparently carrying no detectable risk at all.

The absence of NAION signals with Rybelsus — the oral formulation — is itself an important clue, potentially pointing toward injectable-specific pharmacokinetic factors or the lower effective dose achieved by oral delivery. Understanding why the oral form appears safer could ultimately guide the development of next-generation GLP-1 therapies with reduced ocular risk.

For now, the message is one of informed vigilance. The drugs that have revolutionized diabetes and obesity treatment are not being recalled, nor should they be based on current evidence. But the emerging dose-dependent signal demands that the conversation between doctor and patient includes a frank discussion of what happens when the same molecule, at a slightly higher dose, may carry a dramatically different risk to one of the most vulnerable structures in the human body.